Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing dose-dependent exposure and clinical activity [2][3] - The disease control rate (DCR) was reported at 49.3%, with notable reductions in tumor-specific biomarkers such as PSA and CEA [2][3] - The treatment was well-tolerated, with most adverse events being Grade 2 or less, and immune-related adverse events indicating on-target immune activation [3][4] Therapeutic Potential - NX-1607 targets a previously unaddressed pathway in immune regulation, affecting multiple immune cell types, which may enhance its efficacy in treating solid tumors [2][6] - The results are particularly promising for tumor types like micro-satellite stable colorectal cancer and metastatic prostate cancer, where current immunotherapies have shown limited efficacy [4]